Customer Approval Delays Extended Beyond June
Multiple customers have postponed on-site audits to March/April/May, pushing final approvals beyond initial Q1 timelines. Some customers may wait for Patanjali's larger capacity instead of Dahej.
NEOGEN / Q3-FY26 / risks
Keep the risk register visible.
Neogen Chemicals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Working Capital Deterioration
Inventory DSO and receivables increased due to toll manufacturing transition and inventory build-up ahead of Dahej restart. Target of 140-160 days inventory by FY27 year-end may pressure cash flows.
Inorganic Segment Volume Decline
Excluding Neoen Ionics, inorganic chemical revenue trend is downward, solely attributed to lithium price decline. Management expects Q4/Q1 benefit from recent lithium price spike.
Morita JV Equity Receipt Pending
$20M (~$170 crore) equity from Morita is delayed pending bank approval for asset separation into subsidiary. Expected by Q1 FY27 but dependent on regulatory processes.